Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
PharmaShots
Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025)Â
Shots: The two decades from 2006 to 2025 reflect one of the most transformative periods in biopharma history, characterized by scientific breakthroughs, strategic consolidation, and remarkable commercial growth. The industry successfully navigated patent expirations, global economic downturns, biosimilar competition, pricing reforms, and the unprecedented COVID-19 pandemic while continuing to deliver innovative therapies. Mergers and acquisitions… The post Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025) appeared first on PharmaShots.
Read Full Article
Pharma Tech
Bayer banks €3bn in Apollo contraceptives division deal
Bayer's agreement with Apollo comes a little after Bayer broke its pharma dealmaking fast by acquiring Perfuse Therapeutics in May 2026.
Read Full Article
Pharma Tech
Chinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RA
The funds will support the progression of MindRank’s pipeline, which is heavily dominated by obesity indications.
Read Full Article
Pharma Tech
Ipsen set to rival Botox after duo of Phase III migraine wins
Ipsen claims that Dysport has become the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.
Read Full Article
Pharma Tech
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus to treat multiple sclerosis.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Jul 11, 2026, 2:04 AM
US FDA approves Sanofi's wearable injector form of blood cancer drug
The approval boosts the French ​drugmaker as new CEO Belen Garijo seeks to address investor concerns about reliance ​on asthma drug Dupixent, its biggest-selling medicine.
PharmaShots
Jul 10, 2026, 1:30 PM
Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025)Â
Shots: The two decades from 2006 to 2025 reflect one of the most transformative periods in biopharma history, characterized by scientific breakthroughs, strategic consolidation, and remarkable commercial growth. The industry successfully navigated patent expirations, global economic downturns, biosimilar competition, pricing reforms, and the unprecedented COVID-19 pandemic while continuing to deliver innovative therapies. Mergers and acquisitions… The post Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2006-2025) appeared first on PharmaShots.
Pharma Tech
Jul 10, 2026, 1:11 PM
Bayer banks €3bn in Apollo contraceptives division deal
Bayer's agreement with Apollo comes a little after Bayer broke its pharma dealmaking fast by acquiring Perfuse Therapeutics in May 2026.
PharmaShots
Jul 10, 2026, 12:30 PM
Hansoh Reports P-III (ARTEMIS-008) Trial Data on Risvutatug Rezetecan for Advanced or Relapsed SCLC
Shots: Ref: Hansoh |  Image: Hansoh  | Press Release Related News: Hansoh Pharmaceutical Reports the EC Approval of Aumseqa for Non-small Cell Lung Cancer (NSCLC) PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Hansoh Reports P-III (ARTEMIS-008) Trial Data on Risvutatug Rezetecan for Advanced or Relapsed SCLC appeared first on PharmaShots.
PharmaShots
Jul 10, 2026, 11:30 AM
Viz.ai Partners with Cortechs.ai to Expand AI Platform into Neurodegenerative Disease Care
Shots: Ref: Businesswire |  Image: Viz.ai & Cortechs.ai  | Press Release Related News: Viz.ai Enters a Multi-Year Partnership with Sanofi and Regeneron to Improve Management and Care of COPD PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Viz.ai Partners with Cortechs.ai to Expand AI Platform into Neurodegenerative Disease Care appeared first on PharmaShots.
ET Pharma
Jul 10, 2026, 11:11 AM
Bayer gets €3 billion in Apollo deal for contraceptives unit
Apollo funds and affiliates would take a minority, non-controlling stake in a new entity holding the LARC business, while Bayer keeps a majority stake and "complete operational control."
News
Latest industry coverage
Google News
Jul 12, 2026, 7:59 PM
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance? - The Motley Fool
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?  The Motley Fool
Google News
Jul 12, 2026, 6:58 PM
Pharma body renews push for data protection - The Economic Times
Pharma body renews push for data protection  The Economic Times
Google News
Jul 12, 2026, 6:37 PM
Amgen stock holds steady as biotech pipeline and U.S. market presence underpin long-term story - ad-hoc-news.de
Amgen stock holds steady as biotech pipeline and U.S. market presence underpin long-term story  ad-hoc-news.de
Google News
Jul 12, 2026, 5:43 PM
Teva Pharmaceutical Industries (NYSE:TEVA) Cut to "Hold" at Wall Street Zen - MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) Cut to "Hold" at Wall Street Zen  MarketBeat
Google News
Jul 12, 2026, 5:19 PM
Sumitomo Mitsui Trust Group Inc. Has $65.48 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $65.48 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVAÂ Â MarketBeat
Google News
Jul 12, 2026, 3:35 PM
Pharma Q1 Results Preview: Strong Sales Expected, But Margins Could Shrink; Know Why Goldman Sachs Is Cautious - Goodreturns
Pharma Q1 Results Preview: Strong Sales Expected, But Margins Could Shrink; Know Why Goldman Sachs Is Cautious  Goodreturns
Google News
Jul 12, 2026, 3:16 PM
Divert Valves Market Growth Outlook to 2035: Automation and Hygienic Design Fuel Demand - News and Statistics - IndexBox
Divert Valves Market Growth Outlook to 2035: Automation and Hygienic Design Fuel Demand - News and Statistics  IndexBox
Google News
Jul 12, 2026, 3:10 PM
A good new drug candidate does not immediately become a good drug. The value of a drug depends on ho.. - ë§¤ěťĽę˛˝ě ś
A good new drug candidate does not immediately become a good drug. The value of a drug depends on ho..Â Â ë§¤ěťĽę˛˝ě ś
Google News
Jul 12, 2026, 12:16 PM
The $480bn Novo Nordisk Meltdown: What Went Wrong at Europe’s Pharma Champion - European Business Magazine
The $480bn Novo Nordisk Meltdown: What Went Wrong at Europe’s Pharma Champion  European Business Magazine
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer